DOCSLIB.ORG

IFU PCP Phencyclidine Monlabtest Strip English

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
IFU PCP Phencyclidine Monlabtest Strip English In the absence of the drug in the urine, the colored antibody-colloid gold conjugate moves with the sample fluid by capillary action along the membrane until it reaches the immobilized drug conjugate in the test band PCP PHENCICLIDINE region. At this point, the antibody-colloid gold conjugate reacts with the ® MonlabTest pre-coated drug conjugate to produce a visible pink colored line as the antibodies form complexes with the drug conjugate. The formation of a visible color line on the test band region indicates the urine sample tested is negative for phencyclidine. When the drug is present in the urine, the drug/metabolite antigen will Product code: compete with the drug conjugate coated in the test band region for the PRESENTATIO N limited antibody sites. When a sufficient concentration of drug is present, it MO-806018 20 strips MonlabTest will fill the limited antibody binding sites, and thus preventing the REF attachment of the colored antibody-colloid gold conjugate to drug Only for in vitro diagnostic use conjugates pre-coated in the test band region. An absence of the color band on the test region indicates a positive result . INTENDED USE A control band with a different antigen/antibody reaction is also added to The PCP Phencyclidine MonlabTest ® is a simple, one-step membrane strip to indicate that the test is performed properly. This control immunochromatographic assay intended for professional use only in the line should always be seen. A negative urine sample produces two distinct qualitative detection of Phencyclidine (PCP) and its metabolites in human color bands. A positive sample produces only one color band in the control urine with a cutoff at 25ng/ml. zone. If insufficient sample volume is used, there may not be a Control line, indicating the test is invalid. Note: This test provides only a preliminary analytical result which should be confirmed by a more specific method. Gas chromatography/mass MATERIALS PROVIDED spectrometry (GC/MS) has been established as the preferred confirmatory method by the National Institute on Drug Abuse (NIDA). 1) PCP Phencyclidine MonlabTest ® Clinical consideration and professional judgment should be applied to any 2) Instructions for use drug of abuse test result, particularly when preliminary positive results are indicated. MATERIALS NEEDED BUT NOT PROVIDED SUMMARY & EXPLANATION 1) Clean glass or plastic container for specimens collection 2) Timer Phencyclidine, commonly known as PCP or “angel dust,” is a sympathomimetic dissociative anesthetic whose biological effects include REAGENTS false feelings of invincibility, flashbacks, and even psychosis. It is used primarily as a recreational drug for its hallucinogenic effects. It is 1) Coated Antibodies/Antigens: usually taken orally, by inhalation, insufflation or intravenously. It is a. Control region (C): Goat anti-mouse (IgG) polyclonal antibody well absorbed by the body following all routes of administration b. Test region (T): Phencyclidine-BSA conjugate concentrating fastest in the fatty tissues and the brain. PCP is 2) Labeled Antibodies: metabolized by the liver via hydroxylation, which produces metabolites Colloidal gold conjugate of mouse monoclonal anti- Phencyclidine that are excreted by the kidneys. About 9% of phencyclidines are antibody excreted in the urine in unchanged form. The effects of phencyclidines generally last 4–6 hours following use and the drug has a half-life from SPECIMEN COLLECTION 8-55 hours depending on quantity consumed, body size, metabolic rate and other factors unique to the user. Statistically, the average half-life A fresh urine specimen should be used, no special pre-treatment is is 18 hours. necessary. Specimens should be collected in a clean glass or plastic container. The specimen may be refrigerated (2-8°C) and stored up to 2 The PCP Phencyclidine MonlabTest ® is a fast, qualitative, and visually days. For longer storage, freeze samples at -20°C or below. Refrigerated or read, immunoassay for screening without the use of an instrument. The frozen samples should be allowed to come to room temperature before method employs a unique monoclonal antibody to selectively identify assaying. Urine samples exhibiting visible precipitates should be filtered, Phencyclidine in test urine at or above the concentration of 25ng/mL. centrifuged or allowed to settle, so that clear aliquots can be obtained for This product is not intended to monitor drug levels, but only to screen testing. Urine samples within the normal urine pH range (4.5-8.0) do not urine for the presence of Phencyclidine. require prior adjustment. Adulteration of the urine sample may cause erroneous results. If adulteration is suspected, obtain another sample. PRINCIPLE OF THE TEST TEST PROCEDURE The PCP Phencyclidine MonlabTest ® is based on the principle of a competitive inhibition immunoassay, in which a chemically labeled drug 1. When you are ready to begin testing, open the sealed pouch by (drug conjugate) competes with the drug which may be present in urine tearing along the notch. Remove the test kit from the pouch and for the limited number of antibody binding sites. The test device consists use it as soon as possible. of a membrane strip, which is pre-coated with phencyclidine-BSA conjugate on the test band region, and a colored anti- phencyclidine 2. Immerse the strip into the urine sample with the arrow end monoclonal antibody-colloid gold conjugate pad placed at the end of the pointing towards the urine. Do not immerse past the Mark line. membrane. Take the strip out after 10-15 seconds and lay the strip flat on a clean, dry, non-absorbent surface (e.g., mouth of the urine container). Code: MO-806018 Monlab SL Selva de Mar 48 08019 BCN +34 93 433 58 60 Fax +34 93 436 38 94 [email protected] www.monlab.es Rev: december 2012 4. This test has been developed for testing urine samples only. The 3. Wait for colored bands to appear. Read results in 5 minutes. It performance of this test using other specimens has not been substantiated. is important that the background is clear before the result is 5. Adulterated urine samples may produce erroneous results. Strong read. Results obtained after more than 10 minutes are not oxidizing agents such as bleach (hypochlorite) can oxidize drug analytes. If considered valid. a sample is suspected of being adulterated, obtain a new sample. 6. As the PCP Phencyclidine MonlabTest ® for phencyclidine is a competitive assay, no prozone effect is present. 7. Samples containing target drug concentrations below the cutoff sensitivity for the test may produce a positive result occasionally. 8. Result read after 10 minutes may not be consistence with the original reading obtain within the result window within 5-10 minutes. PERFORMANCE CHARACTERISTICS ® Do not exceed the Sensitivity – PCP Phencyclidine MonlabTest has been shown to detect Mark li ne 25ng/ml of Phencyclidine (PCP) in urine at 10-15 minutes. The cutoff was determined by three people performed using the purchased controls (Cerilliant). Controls were diluted in drug-free urine to give concentrations INTERPRETATION OF RESULTS at 0%, 50%, 75%, 100%, 125% and 150% of the cutoff listed. A total of 15 samples were made at each concentration for Phencyclidine (PCP). The Negative: In addition to one pink colored control (C) line in the following results were tabulated in Table 1. control region, a distinct pink colored line will also appear in the test (T) region. The color intensity of the test line may be weaker or stronger than Table 1- Sensitivity Study on Phencyclidine (PCP) Test Kit that of the control line. Phencyclidine (PCP) 0 12.5 18.75 25 31.25 37.5 Positive: Only one pink colored line appears in the control (C) region. (ng/mL) No apparent line in the test (T) region. This indicates the presence phencyclidine at a level of 25ng/mL or above. Positive 0 0 1 14 14 15 Invalid: No line appears in the control zone “C”, the test should be Negative 15 15 14 1 1 0 voided since an improper test procedure may have been performed or deterioration of reagents may have occurred. This is due o the internal control built in which a distinct control region (C) line always appears. Specificity - The specificity of the PCP Phencyclidine MonlabTest ® was Repeat the test using a new device. If the problem persists, discontinue determined by adding various drugs and drug metabolites to drug-free using the test kit immediately and contact your local distributor. control urine specimens and tested with the kit. The results are expressed in terms of the concentration required to produce a positive result. Note : A faint line on the test region indicates the phencyclidine in sample is near the cut-off level for the test. These samples should be re-tested or Interfering Substances - The following compounds exhibited no confirmed with a more specific method before a clinical determination is interference when dissolved in drug-free control urine at 100µg/ml (Table made. 2). PH and specific gravity studies completed concurrently on the spiked drug-free control urine specimens also showed that there was no interference between the intended results. Table 2 Non-Cross Reacting Compounds (100µg/ml) Ac etaminophen (+) -Naproxen Pentazocaine Control Line Acetone (+/ -)-Ephedrine Pentermine Acetylsalicylic Acid (+/ -)-Isoproterenol Phenothiazine Albumin (+/ -)-Norephedrine Procaine Test Line Aminopyrine Ecgonine Promethazine Amitriptyline Ecgonine Methyl Ester Propanol Amoxici llin Erythromycin Quinidine Ampicillin Estradiol Quinine Aspartame Ethanol Raboflavin Aspirin Fenoprofen Ranitidine Mark Line Atropine Furosemide Salicylic acid Benzoic acid Glucose Serotonin Bilirubin Graiacol glycery ether Sodium Chloride LIMITATIONS Negative Positive Invalid Caffeine Hemoglobi n Sulfamethazine Cannabidiol Histamine Sulfate Benzocaine 1. This test is a qualitative, competitive screening assay. It is not Chloroquine Hydrocortisone Sulindac Chlorpromazine Ibuprofen Temazepam designed to determine the quantitative concentration of drugs or the Clonazepam Imipramine Tetracycline level of intoxication.
Load more

Recommended publications
  • DEMAND REDUCTION a Glossary of Terms
    UNITED NATIONS PUBLICATION Sales No. E.00.XI.9 ISBN: 92-1-148129-5 ACKNOWLEDGEMENTS This document was prepared by the: United Nations International Drug Control Programme (UNDCP), Vienna, Austria, in consultation with the Commonwealth of Health and Aged Care, Australia, and the informal international reference group. ii Contents Page Foreword . xi Demand reduction: A glossary of terms . 1 Abstinence . 1 Abuse . 1 Abuse liability . 2 Action research . 2 Addiction, addict . 2 Administration (method of) . 3 Adverse drug reaction . 4 Advice services . 4 Advocacy . 4 Agonist . 4 AIDS . 5 Al-Anon . 5 Alcohol . 5 Alcoholics Anonymous (AA) . 6 Alternatives to drug use . 6 Amfetamine . 6 Amotivational syndrome . 6 Amphetamine . 6 Amyl nitrate . 8 Analgesic . 8 iii Page Antagonist . 8 Anti-anxiety drug . 8 Antidepressant . 8 Backloading . 9 Bad trip . 9 Barbiturate . 9 Benzodiazepine . 10 Blood-borne virus . 10 Brief intervention . 11 Buprenorphine . 11 Caffeine . 12 Cannabis . 12 Chasing . 13 Cocaine . 13 Coca leaves . 14 Coca paste . 14 Cold turkey . 14 Community empowerment . 15 Co-morbidity . 15 Comprehensive Multidisciplinary Outline of Future Activities in Drug Abuse Control (CMO) . 15 Controlled substance . 15 Counselling and psychotherapy . 16 Court diversion . 16 Crash . 16 Cross-dependence . 17 Cross-tolerance . 17 Custody diversion . 17 Dance drug . 18 Decriminalization or depenalization . 18 Demand . 18 iv Page Demand reduction . 19 Dependence, dependence syndrome . 19 Dependence liability . 20 Depressant . 20 Designer drug . 20 Detoxification . 20 Diacetylmorphine/Diamorphine . 21 Diuretic . 21 Drug . 21 Drug abuse . 22 Drug abuse-related harm . 22 Drug abuse-related problem . 22 Drug policy . 23 Drug seeking . 23 Drug substitution . 23 Drug testing . 24 Drug use .
    [Show full text]
  • Control Substance List
    Drugs DrugID SubstanceName DEANumbScheNarco OtherNames 1 1-(1-Phenylcyclohexyl)pyrrolidine 7458 I N PCPy, PHP, rolicyclidine 2 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine 9663 I Y PEPAP, synthetic heroin 3 1-[1-(2-Thienyl)cyclohexyl]piperidine 7470 I N TCP, tenocyclidine 4 1-[1-(2-Thienyl)cyclohexyl]pyrrolidine 7473 I N TCPy 5 13Beta-ethyl-17beta-hydroxygon-4-en-3-one 4000 III N 6 17Alpha-methyl-3alpha,17beta-dihydroxy-5alpha-androstane 4000 III N 7 17Alpha-methyl-3beta,17beta-dihydroxy-5alpha-androstane 4000 III N 8 17Alpha-methyl-3beta,17beta-dihydroxyandrost-4-ene 4000 III N 9 17Alpha-methyl-4-hydroxynandrolone (17alpha-methyl-4-hyd 4000 III N 10 17Alpha-methyl-delta1-dihydrotestosterone (17beta-hydroxy- 4000 III N 17-Alpha-methyl-1-testosterone 11 19-Nor-4-androstenediol (3beta,17beta-dihydroxyestr-4-ene; 4000 III N 12 19-Nor-4-androstenedione (estr-4-en-3,17-dione) 4000 III N 13 19-Nor-5-androstenediol (3beta,17beta-dihydroxyestr-5-ene; 4000 III N 14 19-Nor-5-androstenedione (estr-5-en-3,17-dione) 4000 III N 15 1-Androstenediol (3beta,17beta-dihydroxy-5alpha-androst-1- 4000 III N 16 1-Androstenedione (5alpha-androst-1-en-3,17-dione) 4000 III N 17 1-Methyl-4-phenyl-4-propionoxypiperidine 9661 I Y MPPP, synthetic heroin 18 1-Phenylcyclohexylamine 7460 II N PCP precursor 19 1-Piperidinocyclohexanecarbonitrile 8603 II N PCC, PCP precursor 20 2,5-Dimethoxy-4-(n)-propylthiophenethylamine 7348 I N 2C-T-7 21 2,5-Dimethoxy-4-ethylamphetamine 7399 I N DOET 22 2,5-Dimethoxyamphetamine 7396 I N DMA, 2,5-DMA 23 3,4,5-Trimethoxyamphetamine
    [Show full text]
  • Drugs of Abuseon September Archived 13-10048 No
    U.S. DEPARTMENT OF JUSTICE DRUG ENFORCEMENT ADMINISTRATION WWW.DEA.GOV 9, 2014 on September archived 13-10048 No. v. Stewart, in U.S. cited Drugs of2011 Abuse EDITION A DEA RESOURCE GUIDE V. Narcotics WHAT ARE NARCOTICS? Also known as “opioids,” the term "narcotic" comes from the Greek word for “stupor” and originally referred to a variety of substances that dulled the senses and relieved pain. Though some people still refer to all drugs as “narcot- ics,” today “narcotic” refers to opium, opium derivatives, and their semi-synthetic substitutes. A more current term for these drugs, with less uncertainty regarding its meaning, is “opioid.” Examples include the illicit drug heroin and pharmaceutical drugs like OxyContin®, Vicodin®, codeine, morphine, methadone and fentanyl. WHAT IS THEIR ORIGIN? The poppy papaver somniferum is the source for all natural opioids, whereas synthetic opioids are made entirely in a lab and include meperidine, fentanyl, and methadone. Semi-synthetic opioids are synthesized from naturally occurring opium products, such as morphine and codeine, and include heroin, oxycodone, hydrocodone, and hydromorphone. Teens can obtain narcotics from friends, family members, medicine cabinets, pharmacies, nursing 2014 homes, hospitals, hospices, doctors, and the Internet. 9, on September archived 13-10048 No. v. Stewart, in U.S. cited What are common street names? Street names for various narcotics/opioids include: ➔ Hillbilly Heroin, Lean or Purple Drank, OC, Ox, Oxy, Oxycotton, Sippin Syrup What are their forms? Narcotics/opioids come in various forms including: ➔ T ablets, capsules, skin patches, powder, chunks in varying colors (from white to shades of brown and black), liquid form for oral use and injection, syrups, suppositories, lollipops How are they abused? ➔ Narcotics/opioids can be swallowed, smoked, sniffed, or injected.
    [Show full text]
  • Advisory Council on the Misuse of Drugs Chair: Professor Les Iversen Secretary: Rachel Fowler 3Rd Floor Seacole Building 2
    ACMD Advisory Council on the Misuse of Drugs Chair: Professor Les Iversen Secretary: Rachel Fowler 3rd Floor Seacole Building 2. Marsham Street London SW1P 4DF 020 7035 0454 Email: [email protected] Rt Hon. Theresa May MP Home Office 2 Marsham Street London SW1P 4DF 18th October 2012 Dear Home Secretary, In March 2012 the ACMD advised that methoxetamine be subject to a temporary class drug order. Methoxetamine was marketed as a legal alternative to ketamine until a temporary class drug order was implemented in April 2012. As is now required, the ACMD has followed its initial assessment with a consideration of methoxetamine in the context of the Misuse of Drugs Act 1971; I enclose the report with this letter. The chemical structure of methoxetamine bears a close resemblance to that of both ketamine and phencyclidine (PCP, „Angel Dust‟, a class A drug), which both produce well- documented and serious adverse effects following both acute and chronic usage. Users report that the effects of methoxetamine are similar to those of ketamine, however, some users report that the effects are of longer duration.The harmful effects reported include severe dissociation, cardiovascular symptoms, paranoid thoughts and unpleasant hallucinations. The first analytically confirmed series reported by Guy‟s and St Thomas‟ NHS Foundation Trust, London in 2011, was of three individuals who presented having self-reported use of methoxetamine. All three presented with a ketamine-like dissociative state, but also had significant stimulant effects with agitation and cardiovascular effects including tachycardia and hypertension. Toxicological screening of serum samples confirmed methoxetamine use in two of the cases.
    [Show full text]
  • Designer Drugs: a Review
    WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES Chavan et al. World Journal of Pharmacy and Pharmaceutical Sciences SJIF Impact Factor 5.210 Volume 4, Issue 08, 297-336. Review Article ISSN 2278 – 4357 DESIGNER DRUGS: A REVIEW Dr. Suyash Chavan,MBBS*1 and Dr. Vandana Roy2 1MD, Resident Doctor, Department of Pharmacology, Maulana Azad Medical College, New Delhi. 2MD, PhD Professor, Department of Pharmacology, Maulana Azad Medical College, New Delhi. ABSTRACT Article Received on 25 May 2015, Designer drugs‟ are psychoactive substances that mimic the effects of Revised on 16 June 2015, other banned illicit drugs but evade detection by law enforcing Accepted on 07 July 2015 agencies. This is because of modifications in the structure of the original psychoactive molecule. Originally developed as a way to *Correspondence for evade existing drug laws in the late 1960s, the synthesis and use of Author designer drugs has increased dramatically. They are advertised with Dr. Suyash Chavan innocuous names and are sold mostly over the internet, discreet outlets MD, Resident Doctor, Department of and at entertainment clubs. Victims may exhibit symptoms similar to Pharmacology, Maulana the effects of the illegal drug that these synthetic drugs mimic, Azad Medical College, however, the exact culprit drug is not detected due to structural New Delhi. modifications in the new drug. Overdose of these drugs may lead to serious adverse effects that can be life threatening. Understanding the pharmacology and toxicology of these agents is essential to facilitate their detection and to provide better medical care for patients suffering from adverse effects due to their consumption.
    [Show full text]
  • Proposal for Reclassification of Cough Medicines Containing Dextromethorphan, Opium Tincture, Squill Oxymel and Pholcodine to Restricted Medicines
    Proposal for reclassification of cough medicines containing dextromethorphan, opium tincture, squill oxymel and pholcodine to restricted medicines Purpose Medsafe has recently been alerted to instances of abuse of cough medicines containing dextromethorphan. Concern was raised over the easy availability of opioid (and opioid-like) cough medicines which can be bought at a pharmacy or supermarket without healthcare professional supervision. Dextromethorphan is a substance that does not belong to the opioid family but has a chemical structure closely resembling the opioids. Dextromethorphan has a history of abuse in New Zealand and other countries. There are also other cough medicines available as pharmacy medicines which have been noted as at least having a potential for abuse, for example cough medicines containing pholcodine and Gees linctus which contains anhydrous morphine. Pholcodine and anhydrous morphine are both opioids. Medsafe therefore requests that Medicines Classification Committee (MCC) considers reclassification of dextromethorphan, opium tincture, squill oxymel and pholcodine containing products to Pharmacist-Only (restricted) medicines. Medsafe considers that a reclassification to restricted medicine balances a need for better supervision whilst maintaining access for those who benefit from using these medicines. Background Dextromethorphan and misuse (1) Dextromethorphan (DXM) is the D- isomer of the codeine synthetic analogue, levorphanol. DXM also structurally resembles ketamine and phenycycline which are dissociative agents, meaning that they can be used to incite a type of general anesthesia characterized by analgesia and amnesia with minimal effect on respiratory function. DXM is an opioid, but because of its stereochemistry, DXM and its metabolites do not bind to the mu and delta opioid receptors, thus avoiding classic opioid toxicity.
    [Show full text]
  • University of Groningen Stereoselectivity in the Hepatic Metabolism and Transport of Quaternary Drugs of the Morphinan Type Lant
    University of Groningen Stereoselectivity in the hepatic metabolism and transport of quaternary drugs of the morphinan type Lanting, Aleida Bartha Louisa IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2000 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Lanting, A. B. L. (2000). Stereoselectivity in the hepatic metabolism and transport of quaternary drugs of the morphinan type. s.n. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 24-09-2021 In this thesisthe potential of some quaternaryamine derivativesof the morphinan analoguesdextrorphan, levorphanol, dextromethorphan and levomethorphanas model compoundswas investigatedto study stereoselectivityin hepatic metabolismand transport of cationic drugs.These model compoundspossess a rigid stereochemicalstructure, resulting in major differencesin receptor affinity. We assumedthat the major influenceof the stereochemicalstructure on the receptor level might also causedifferences in carrier-mediatedtransport and biotransformation processes.
    [Show full text]
  • Urine Drug Toxicology and Pain Management Testing
    Urine Drug Toxicology and Pain Management Testing Kara Lynch, PhD, DABCC University of California San Francisco San Francisco, CA Learning Objectives • Describe what chronic pain is, who is affected and how they are commonly treated • Explain the common methodologies used in pain management testing • Interpret urine drug testing results • Create protocols to minimize the occurrence of false positive or false negative results Pain – definition and types • Pain - an unpleasant sensory and emotional experience associated with actual or potential tissue damage • Chronic pain - pain that extends beyond the expected period of healing • Nociceptive Pain – Pain caused by tissue injury – Stimulus-evoked, high intensity – Opioid sensitive • Neuropathic Pain – Caused by nerve injury – Spontaneous activity – Develops in days or month – Opioid insensitive Chronic Pain Patients • Arthritis • Fibromyalgia – Osteoarthritis • Headaches – Rheumatoid arthritis – Migraine – Gout – Tension • Cancer – Cluster • Chronic non-cancer pain • Myofascial pain • Central pain syndrome • Neuropathic pain – CNS damage – Diabetic Peripheral – Multiple Sclerosis Neuropathy – Parkinson’s disease – Postherpetic neuralgia • Chronic abnominal pain • Neck and Back Pain – Intestinal obstructions Chronic Pain Medications • Opiates • Synthetic opioids – Codeine – Fentanyl – Morphine – Methadone • Semi-synthetic opioids – Meperidine – Oxymorphone – Tramadol – Oxycodone – Propoxyphene – Hydromorphone – Levorphanol – Hydrocodone – Tapentadol – Buprenorphine • Anticonvulsant • Muscle
    [Show full text]
  • Dextrorphan Binds to Opioid Receptors in Guinea-Pig Brain Membranes And
    Proc. Natl. Acad. Sci. USA Vol. 87, pp. 1629-1632, March 1990 Pharmacology Dextrorphan binds to opioid receptors in guinea-pig brain membranes and is an antagonist at opioid receptors in myenteric plexus (binding/guinea-pig ileum/levorphanol/stereoselectivity) AVRAM GOLDSTEIN AND ASHA NAIDU Department of Pharmacology, Stanford University, Stanford, CA 94305 Contributed by Avram Goldstein, December 11, 1989 ABSTRACT Dextrorphan (+)-tartrate, purified by re- LaRoche); [D-Ala,MePhe4,Gly-ol5]enkephalin (DAGO; Pe- peated crystallization to remove all traces of the enantiomer ninsula Laboratories) (2); trans-3,4-dichloro-N-methyl- levorphanol, binds to IL, 6, and K sites on guinea-pig brain N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide methane- membranes with lower affinities (by a factor of400-3200) than sulfonate (U50,488; Upjohn) (3); (-)-naloxone hydrochloride levorphanol. In the guinea-pig ileum myenteric plexus longi- (NAL; Endo Laboratories, New York); normorphine hydro- tudinal muscle preparation (GPI), dextrorphan, at 100-200 chloride (NOR) and (+)-naloxone hydrochloride (National ,uM, inhibits the electrically stimulated twitch, but this action Institute on Drug Abuse); N-methyl-D-aspartic acid (NMDA), is not blocked or reversed by naloxone; both (+)- and (-)- aminophosphonovalerate, norepinephrine (levarterenol), at- naloxone produce similar non-opioid twitch inhibition at com- ropine, and eserine (physostigmine) (Sigma). parable concentrations. At 10-20 jaM, dextrorphan' blocks and Preparation ofDEXp. [3H]LEV (Ro 1-5431/701, Hoffmann- reverses the twitch inhibition due to ,u and KWagonists, but the LaRoche; 17.4 Ci/mmol; 1 Ci = 37 GBq) was purified' by blockade can be overcome only partially by increasing the preparative reversed-phase HPLC (Waters, C18 AgBondaPak, agonist concentration.
    [Show full text]
  • Neurolept Anaesthesia: a Comparison with a Conventional Technique for Major Surgery*
    NEUROLEPT ANAESTHESIA: A COMPARISON WITH A CONVENTIONAL TECHNIQUE FOR MAJOR SURGERY* S. A. McDOWELL,M.B., F./~.A.I~.C.S. AND J. W. DUNDEE, 1VI.D.,PH.D., F.F.A.H.C.S. IN THE PAST DECADE, the term "neuroleptic" has been increasingly used to describe the effects of certain drugs on the central nervous system. It is usually used to signify the production of tranquillity and mental detachment, without a marked soporific effect. If a narcotic analgesic is used in combination with a neuroleptic drug, then a state of neurolept-analgesia is produced and if, in this state, a hypnotic is added to produce sleep, the result is neurolept anaesthesia (NLA). Since the introduction of this form of anaesthesia by De Castro and Mundeleer 1 a great variety of techniques of NLA have been described and many claims made for its advantages over more conventional forms of anaesthesia. 2-6 Among these are: (a) stability of the cardiovascular system, making it particularly suited for the poor-risk patient. (b) profound analgesia, which extends into the postoperative period and results in comfort for the patient and ease of management. (e) little postoperative nausea and vomiting. (d) rapid recovery of consciousness with good tolerance of endotraeheal tubes and patient cooperation. In spite of these advantages, neuroleptanaesthesia has not found acceptance with all workers 7 and recently, the usefulness of the drugs used in NLA has been ques- tioned by workers from this department, s,9 The neuroleptic drug commonly used in this form of anaesthesia is droperidol and it is usually given in conjunction with the analgesic fentanyl.
    [Show full text]
  • Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority
    Chapter 8 – Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority This rule is established under the authority of 18 V.S.A. §§ 4201 and 4202 which authorizes the Vermont Board of Health to designate regulated drugs for the protection of public health and safety. 2.0 Purpose This rule designates drugs and other chemical substances that are illegal or judged to be potentially fatal or harmful for human consumption unless prescribed and dispensed by a professional licensed to prescribe or dispense them, and used in accordance with the prescription. The rule restricts the possession of certain drugs above a specified quantity. The rule also establishes benchmark unlawful dosages for certain drugs to provide a baseline for use by prosecutors to seek enhanced penalties for possession of higher quantities of the drug in accordance with multipliers found at 18 V.S.A. § 4234. 3.0 Definitions 3.1 “Analog” means one of a group of chemical components similar in structure but different with respect to elemental composition. It can differ in one or more atoms, functional groups or substructures, which are replaced with other atoms, groups or substructures. 3.2 “Benchmark Unlawful Dosage” means the quantity of a drug commonly consumed over a twenty-four hour period for any therapeutic purpose, as established by the manufacturer of the drug. Benchmark Unlawful dosage is not a medical or pharmacologic concept with any implication for medical practice. Instead, it is a legal concept established only for the purpose of calculating penalties for improper sale, possession, or dispensing of drugs pursuant to 18 V.S.A.
    [Show full text]
  • Levorphanol Use: Past, Present and Future
    Postgraduate Medicine ISSN: 0032-5481 (Print) 1941-9260 (Online) Journal homepage: http://www.tandfonline.com/loi/ipgm20 Levorphanol Use: Past, Present and Future Jeffrey Gudin, Jeffrey Fudin & Srinivas Nalamachu To cite this article: Jeffrey Gudin, Jeffrey Fudin & Srinivas Nalamachu (2015): Levorphanol Use: Past, Present and Future, Postgraduate Medicine, DOI: 10.1080/00325481.2016.1128308 To link to this article: http://dx.doi.org/10.1080/00325481.2016.1128308 Accepted author version posted online: 03 Dec 2015. Submit your article to this journal View related articles View Crossmark data Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ipgm20 Download by: [Jeffrey Fudin] Date: 03 December 2015, At: 20:32 Publisher: Taylor & Francis Journal: Postgraduate Medicine DOI: 10.1080/00325481.2016.1128308 Levorphanol Use: Past, Present and Future Authors: Jeffrey Gudin1, Jeffrey Fudin2, and Srinivas Nalamachu3 Affiliations: 1Director, Pain Management and Palliative Care, Englewood Hospital and Medical Center, Englewood, NJ, and Clinical Instructor, Anesthesiology, Icahn School of Medicine at Mount Sinai, New York, NY. 2Adjunct Associate Professor, Albany College of Pharmacy and Health Sciences and also Western New England University College of Pharmacy Director, PGY2 Pain Residency and Clinical Pharmacy, Specialist, Pain Management Stratton VA Medical Center, Albany, NY 3President and Medical Director, International Clinical Research Institute, Overland Park, KS, and Adjunct Associate Professor, Temple University School of Medicine, Downloaded by [Jeffrey Fudin] at 20:32 03 December 2015 Philadelphia, PA. Running Title: Levorphanol Use: Past, Present and Future Corresponding Author Srinivas Nalamachu Srinivas R. Nalamachu MD International Clinical Research Institute, Inc.
    [Show full text]